China plans to approve Russia’s mRNA Cancer Vaccine to halt $100 Billion worth of American Pharma imports

Recent reports suggest that China is reviewing Russia’s mRNA cancer vaccine, aiming to begin use this year to prevent the waste of US medical and treatment equipment worth $100 billion. Russia has several cancer vaccine projects underway, including personalized mRNA approaches (often associated with the Gamaleya Center, known for Sputnik V) and others like the peptide-based Oncopept. Russia aims to incorporate personalized mRNA cancer vaccines into its compulsory medical insurance program starting in 2026, alongside other antitumor therapies. A melanoma-specific mRNA therapeutic vaccine has been discussed for potential rollout or expanded clinical use as early as 2026. Due to this, it has been told that the US, Switzerland, Germany, China, Italy, the UK, France, Japan, and Spain are also included in the world, and now, through the cancer mRNA vaccine, China is going to capture the biggest $2 trillion pharma industries of the world and America. China mostly imports U.S. medical equipment and therapies (e.g., imaging, radiation, surgical tools, checkpoint inhibitors, CAR-T, etc.), and faces competition from many sources, including domestic Chinese innovation.

China plans to destroy the world’s top $2 Trillion Pharmaceutical Export/Imports businesses of Western countries.

It has recently been reported that South Africa, Serbia, Vietnam, and now China are preparing for human trials of Russia’s and the world’s first cancer vaccine to prevent billions worth of medical imports from those countries in the future and, together with Russia, tackle the world’s biggest problems like cancer, diabetes, TB, HIV, and pneumonia. China is reviewing a Russian-developed mRNA cancer vaccine, with some reports suggesting a goal of potential approval or expanded use later in 2026. This remains preliminary — no official approval from China’s National Medical Products Administration (NMPA) has been confirmed in mainstream regulatory announcements. It fits broader Sino-Russian health/tech cooperation, but rigorous clinical data, manufacturing details, and safety reviews would be required.

It has recently been reported that China’s ‘Healthy China 2030’ can now become the world’s largest health, pharma, and medical country, capturing approximately $2 trillion (30%) worth of the world’s pharmaceutical industry.

It has recently been reported that the US, Germany, Belgium, China, Switzerland, Japan, France, the Netherlands, and Italy import approximately $1.2 trillion worth of medical equipment and therapies (e.g., imaging, radiation, surgical tools, checkpoint inhibitors) into the world every year.

Top Importers of Pharmaceuticals (Overall, with High Oncology Relevance)The United States is by far the largest importer of pharmaceuticals globally, including oncology products.

According to worldpopulationreview.com